» Articles » PMID: 36410445

Dysregulated Amino Acid Sensing Drives Colorectal Cancer Growth and Metabolic Reprogramming Leading to Chemoresistance

Overview
Specialty Gastroenterology
Date 2022 Nov 21
PMID 36410445
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Colorectal cancer (CRC) is a devastating disease that is highly modulated by dietary nutrients. Mechanistic target of rapamycin complex 1 (mTORC1) contributes to tumor growth and limits therapy responses. Growth factor signaling is a major mechanism of mTORC1 activation. However, compensatory pathways exist to sustain mTORC1 activity after therapies that target oncogenic growth factor signaling. Amino acids potently activate mTORC1 via amino acid-sensing GTPase activity towards Rags (GATOR). The role of amino acid-sensing pathways in CRC is unclear.

Methods: Human colon cancer cell lines, preclinical intestinal epithelial-specific GATOR1 and GATOR2 knockout mice subjected to colitis-induced or sporadic colon tumor models, small interfering RNA screening targeting regulators of mTORC1, and tissues of patients with CRC were used to assess the role of amino acid sensing in CRC.

Results: We identified loss-of-function mutations of the GATOR1 complex in CRC and showed that altered expression of amino acid-sensing pathways predicted poor patient outcomes. We showed that dysregulated amino acid-sensing induced mTORC1 activation drives colon tumorigenesis in multiple mouse models. We found amino acid-sensing pathways to be essential in the cellular reprogramming of chemoresistance, and chemotherapeutic-resistant patients with colon cancer exhibited de-regulated amino acid sensing. Limiting amino acids in in vitro and in vivo models (low-protein diet) reverted drug resistance, revealing a metabolic vulnerability.

Conclusions: Our findings suggest a critical role for amino acid-sensing pathways in driving CRC and highlight the translational implications of dietary protein intervention in CRC.

Citing Articles

Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance.

He H, Zheng S, Jin S, Huang W, Wei E, Guan S Sci Rep. 2025; 15(1):570.

PMID: 39747340 PMC: 11695588. DOI: 10.1038/s41598-024-84353-9.


A whole food, plant-based diet reduces amino acid levels in patients with metastatic breast cancer.

Scales T, Smith B, Blanchard L, Wixom N, Tuttle E, Altman B Cancer Metab. 2024; 12(1):38.

PMID: 39702320 PMC: 11657127. DOI: 10.1186/s40170-024-00368-w.


Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.


A whole food, plant-based diet reduces amino acid levels in patients with metastatic breast cancer.

Scales T, Smith B, Blanchard L, Wixom N, Tuttle E, Altman B medRxiv. 2024; .

PMID: 39417128 PMC: 11483017. DOI: 10.1101/2024.10.09.24315165.


Low protein diet protects the liver from Salmonella Typhimurium-mediated injury by modulating the mTOR/autophagy axis in macrophages.

Wojtowicz E, Hampton K, Moreno-Gonzalez M, Utting C, Lan Y, Ruiz P Commun Biol. 2024; 7(1):1219.

PMID: 39349819 PMC: 11444042. DOI: 10.1038/s42003-024-06932-w.


References
1.
Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X . Genomic Alterations in -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer Res. 2021; 81(9):2470-2480. PMC: 8137641. DOI: 10.1158/0008-5472.CAN-20-3232. View

2.
Bar-Peled L, Chantranupong L, Cherniack A, Chen W, Ottina K, Grabiner B . A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013; 340(6136):1100-6. PMC: 3728654. DOI: 10.1126/science.1232044. View

3.
Corcoran R, Rothenberg S, Hata A, Faber A, Piris A, Nazarian R . TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013; 5(196):196ra98. PMC: 3867020. DOI: 10.1126/scitranslmed.3005753. View

4.
Ro S, Xue X, Ramakrishnan S, Cho C, Namkoong S, Jang I . Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis. Elife. 2016; 5:e12204. PMC: 4805551. DOI: 10.7554/eLife.12204. View

5.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View